Isabelle Mahé on Delphi Consensus on Aspects Relating to the Antithrombotic Therapy for Cancer Patients
Isabelle Mahé, Head of Internal Medicine, Louis Mourier Hospital, APHP, Paris Cité University, reposted from SERENITY on LinkedIn:
”A two-round Delphi process was used to achieve consensus on aspects relating to the antithrombotic therapy deprescribing discussions and process in end-of-life cancer patients across Europe and different specialities.
The perspective is to support informed decision-making, reduce complications, and improve quality of life in palliative care patients.”
Quoting SERENITY‘s post:
”Developing a decision support tool for the continuation or deprescribing of antithrombotic therapy in patients receiving end-of-life care: Results of a European Delphi study
For the DELPHI Serenity Group
Isabelle Mahé Anette Arbjerg Højen
Prof.Dr.Stavros Konstantinides
Sebastian Szmit
Denise Abbel
Laurent Bertoletti
Adrian Edwards
Jacobijn Gussekloo
Johan Langendoen
Simon Mooijaart
Stella Trompet
Erik Klok
Professor Simon Noble
Camille Couffignal”
Read the full article here.
Article: Developing a decision support tool for the continuation or deprescribing of antithrombotic therapy in patients receiving end-of-life care: Results of a European Delphi study
Authors: For the DELPHI Serenity Group – Skerdi Haviarie, Nassima Si Mohammed, Anette Arbjerg Højeng, Carme Fonth, Stavros Konstantinides, Marieke Kruip, Luigi Maiorana, Sebastian Szmit, Denise Abel, Laurent Bertoletti, Adrian Edwards, Michelle Edwards, Alessandra Gaval, Jacobijn Gussekloo, Miriam Johnson, Rashmi Kumar, Johan Langendoen, Kate Lifford, Simon Mooijaart, Mark Pearson, Johanneke Portielje, Kathy Seddon, Stella Trompet, Hélène Helfer, Frederikus Klok, Simon Noble, Camille Couffignal
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 9, 2026, 00:54Mary Catherine Moffett: Advancing Advocacy Together – Highlights from the Sanofi Bleeding Disorders Summit
-
Oct 9, 2026, 00:46Paris Margaritis: Assays vs Outcomes – Connecting FVIII Expression to Bleeding Phenotype in Hemophilia A
-
Oct 9, 2026, 00:39Rodrigo Arreola Diaz: The Rise of Concizumab for Hemophilia A and B
-
Oct 8, 2026, 23:27Shayan Mohammadmoradi: Happy to Be Back at the Midwest Platelet Conference for Its 20th Meeting
-
Oct 8, 2026, 23:18Lorena Arranz: Honoured to Contribute to the 6th Global MPN Symposium
-
Oct 8, 2026, 23:06Denis Oduor: Serving Citizens and Saving Lives Through Blood Donation During National Customer Service Week 2026
-
Oct 8, 2026, 22:51Jan Hartmann: Speaking on Global Trends in Plasma Collection at the 50th Meeting of the Japanese Society of Blood Services
-
Oct 8, 2026, 22:49Akshat Jain: Proud to Announce the Publication of Advances in Sickle Cell Disease
-
Oct 8, 2026, 22:49Ed Shovelin: Extending the Platelet Aggregation Testing Window to 72 Hours